Study Protocols Should Check For Alternative Medicine Use - CDER Seminar
This article was originally published in The Tan Sheet
Executive Summary
Clinical trial entry protocols should include specific questions about complementary and alternative medicine use by patients, Seattle-based Northwest Natural Health-Specialty Care Clinic practitioner Dan Labriola told an FDA Center for Drug Evaluation & Research seminar Feb. 21.
You may also be interested in...
Pediatric Dietary Supplement Trials Needed To Set Standards Of Care
Recommendations concerning supplement use in children cannot be developed without first answering basic questions about safety, efficacy and usage patterns, Ronald Kleinman, MD, Harvard Medical School, stated Feb. 13.
St. John's Wort/HIV Protease Inhibitor Use Warnings Issued By FDA, NIH
HIV patients taking protease inhibitors should avoid taking St. John's wort dietary supplements, FDA and the National Institutes of Health warned Feb. 10, following the release of study results demonstrating the herbal compromises the antiviral drugs' effectiveness.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC